LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

Off #MRK, Health, Health Information, Human Health, Latest News, Life Sciences, Medicine, Merck, Merck Pharmaceutical, NYSE:MRK, Oncology, Oncology Newsroom, Pharmaceuticals, Research and Development News, Science and Health, Science and Research

Dateline City:
KENILWORTH, N.J.

Only PARP Inhibitor to Improve Overall Survival vs. New Hormonal Agent Treatments for Advanced Prostate Cancer, A Key Secondary Endpoint

KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced further positive results from the Phase 3 PROfound trial evaluating LYNPARZA in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation (HRRm) and whose disease had progressed on prior treatment with new hormonal agent (NHA) treatments (e.g. enzalutamide or abiraterone).

Language:
English

Contact:

Media
Pamela Eisele, (267) 305-3558
Steve Wanczyk, (267) 305-5563

Investor
Peter Dannenbaum, (908) 740-1037
Courtney Ronaldo, (908) 740-6132

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer »

About The Author